Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Trulance (plecanatide) is indicated for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Diphenyl Methane Laxatives (Bisacodyl and Sodium Picosulfate): At 4 weeks, these laxatives were ranked first for failure to achieve three or more complete spontaneous bowel movements (CSBMs) per week (RR 0.55, 95% CI 0.48-0.63, P-score 0.99) and for failure to achieve an increase of one or more CSBM per week from baseline (RR 0.44, 95% CI 0.37-0.54, P-score 0.99).
• Prucalopride: At 12 weeks, prucalopride ranked first for failure to achieve three or more CSBMs per week (RR 0.82, 95% CI 0.78-0.86, P-score 0.96) and for failure to achieve an increase of one or more CSBM per week from baseline (RR 0.74, 95% CI 0.66-0.83, P-score 0.79).
• Linaclotide: Showed similar efficacy to prucalopride 2 mg once daily at 12 weeks for failure to achieve an increase of one or more CSBM per week from baseline (P-score 0.76 for linaclotide, 0.71 for prucalopride).
• There is no safety information available in the reviewed studies for plecanatide (Trulance).
• Bisacodyl ranked lowest for safety due to the highest total number of adverse events and abdominal pain (P-score 0.08).
• There is no population types or subgroups information available in the reviewed studies.